|
Jun 25
|
Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?
|
|
Jun 24
|
Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating
|
|
Jun 9
|
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
|
|
Mar 10
|
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
|
|
Mar 1
|
MannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
|
|
Feb 28
|
MannKind Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Feb 27
|
MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
|
|
Feb 27
|
MannKind (MNKD) Q4 2024 Earnings Call Transcript
|
|
Feb 27
|
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics
|
|
Feb 26
|
MannKind (MNKD) Q4 Earnings Meet Estimates
|
|
Feb 26
|
MannKind: Q4 Earnings Snapshot
|
|
Feb 26
|
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
|
|
Feb 24
|
Exploring Three High Growth Tech Stocks in the United States
|
|
Feb 24
|
Unveiling MannKind (MNKD) Q4 Outlook: Wall Street Estimates for Key Metrics
|
|
Feb 19
|
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
|
|
Oct 9
|
MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ...
|
|
Oct 9
|
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
|
|
Oct 7
|
Why MannKind (MNKD) Could Beat Earnings Estimates Again
|
|
Sep 30
|
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
|
|
Jul 17
|
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
|